Intellia Therapeutics Inc earnings beat by 0.05, revenue topped estimates
NTLA Stock | USD 12.12 0.07 0.58% |
About 61% of Intellia Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Intellia Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Intellia Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Intellia Therapeutics stock news signals to limit their universe of possible portfolio assets.
Intellia |
Intellia Therapeutics Inc earnings beat by 0.05, revenue topped estimates
Read at investing.com
Intellia Therapeutics Current Investor Sentiment
Panic Vs Confidence
39
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Intellia Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Intellia Therapeutics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Intellia Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Intellia Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Intellia Therapeutics Historical Investor Sentiment
Investor biases related to Intellia Therapeutics' public news can be used to forecast risks associated with an investment in Intellia. The trend in average sentiment can be used to explain how an investor holding Intellia can time the market purely based on public headlines and social activities around Intellia Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Intellia Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Intellia Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Intellia Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Intellia Therapeutics.
Intellia Therapeutics Fundamental Analysis
We analyze Intellia Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intellia Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intellia Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earnings To Growth
Price To Earnings To Growth Comparative Analysis
Intellia Therapeutics is currently under evaluation in price to earnings to growth category among its peers. PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Intellia Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Intellia Therapeutics stock to make a market-neutral strategy. Peer analysis of Intellia Therapeutics could also be used in its relative valuation, which is a method of valuing Intellia Therapeutics by comparing valuation metrics with similar companies.
Peers
Intellia Therapeutics Related Equities
DNA | Ginkgo Bioworks | 9.07 | ||||
PRME | Prime Medicine, | 5.07 | ||||
EDIT | Editas Medicine | 1.65 | ||||
VRTX | Vertex Pharmaceuticals | 0.61 | ||||
CRBU | Caribou Biosciences | 0.59 | ||||
CRSP | Crispr Therapeutics | 0.39 | ||||
VERV | Verve Therapeutics | 0.00 | ||||
BEAM | Beam Therapeutics | 0.38 | ||||
FATE | Fate Therapeutics | 2.41 | ||||
SANA | Sana Biotechnology | 2.86 |
Complementary Tools for Intellia Stock analysis
When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |